Flow Cytometry Market Expected to Reach $16.6 Billion by 2032—Allied Market Research

According to a new report published by Allied Market Research, titled, “Flow Cytometry Market," The flow cytometry market size was valued at $6.2 billion in 2022, and is estimated to reach $16.6 billion by 2032, growing at a CAGR of 10.3% from 2023 to 2032. Flow cytometry is a powerful analytical technique used in biology and medicine to characterize and quantify various properties of cells and particles in a fluid suspension. The key component of a flow cytometer is a flow cell, which houses the sample and directs it into the laser beam. As cells pass through the laser, they scatter light in multiple directions and emit fluorescent signals if labeled with specific fluorescent dyes or antibodies. These signals are then collected by detectors and converted into data, generating detailed information about cell size, shape, complexity, and the presence or absence of specific molecules on their surface. 

The flow cytometry market is gaining prominence in recent years, owing to high adoption of flow cytometry in developing cell-based therapies and rise in incidence of chronic diseases. 

The high adoption of flow cytometry in developing cell-based therapies has emerged as a major driver in the flow cytometry market. This burgeoning trend is rooted in the pivotal role that flow cytometry plays in the field of regenerative medicine and cell therapy. Flow cytometry, with its ability to analyze and sort cells, based on various characteristics such as size, shape, and surface markers, has become an indispensable tool for researchers and clinicians working on cell-based therapies. For instance, according to a 2020 report by National Institute of Standards and Technology, it was reported that flow cytometry has been critical for establishing identity, purity, and potency for Chimeric Antigen Receptor (CAR)-T cell manufacturing; and associated data to support the approval of Biological License Applications (BLA) by the U.S. Food and Drug Administration (FDA) and the approval by the European Medicines Agency (EMA).  

Thus, as the field of regenerative medicine continues to advance, with promising breakthroughs in areas like immunotherapy and tissue engineering, the demand for flow cytometry is on the rise that is anticipated to boost the flow cytometry market size. The rise in the incidence of chronic diseases such as human immunodeficiency virus, leukemia or lymphoma, and cancer, has emerged as a significant driver in the flow cytometry market. For human immunodeficiency virus diagnosis, flow cytometry is employed to assess immune cell counts and their activation status, aiding in the management of antiretroviral therapy.  

For instance, according to a 2023 report by the National Library of Medicine, the immunofluorescence analysis by flow cytometry is the gold standard for diagnosis of HIV through the absolute count of CD4 T lymphocytes procedure. Additionally, in hematological malignancies such as leukemia and lymphoma, flow cytometry enables precise classification of different cell types, helping clinicians tailor treatment plans for improved patient outcomes. Furthermore, in the realm of cancer, flow cytometry has been instrumental in identifying cancer stem cells, studying tumor microenvironments, and evaluating the efficacy of immunotherapies. Thus, the rise in incidence of chronic diseases is expected to drive the demand of flow cytometry owing to its accurate diagnosis of the disease that are anticipated to boost the flow cytometry market share. 

However, the high cost of instruments poses a significant restraint for the flow cytometry market, impeding its widespread acceptance and adoption. Flow cytometry is a powerful analytical technique used in various applications, including cell biology, immunology, cancer research, and clinical diagnostics. However, the sophisticated nature of flow cytometers, coupled with the advanced technologies they employ, contributes to their steep price tags.  

These instruments incorporate complex optics, lasers, detectors, and data analysis software, necessitating substantial investments in research and development, manufacturing, and maintenance. Moreover, the integration of Artificial Intelligence (AI) in flow cytometry represents a significant growth opportunity within the flow cytometry market. 

On the basis of component, the flow cytometry industry is bifurcated into instruments, reagents and consumables, software and services. The reagents and consumables segment accounted for the highest market share in 2022, owing to high adoption of reagents in almost every procedure of flow cytometry.  

On the basis of technology, the flow cytometry industry is segmented into cell-based flow cytomtry and bead-based flow cytometry. The cell-based flow cytometry segment was the highest revenue generating segment in 2022, owing to its wide scale application in the diagnosis of various diseases such as cancer and HIV, biomedical research, and its increasing use in monitoring the progress of drug treatment.  

On the basis of application, academic & clinical applications segment accounted for the highest share of the flow cytometry market share in 2022, owing to increase in adoption of flow cytometer in the cell cycle analysis & cell proliferation. However, the diagnostic applications segment is expected to exhibit the fastest growth during the forecast period, owing to a rise in the use of technology in diagnostic applications. 

On the basis of end user, the flow cytometry market analysis is segmented into hospitals, medical schools and clinical testing labs, commercial organizations, academic institutions and others. The commercial organizations segment accounted for a major share of the market share in the flow cytometry market in 2022, owing to heavy investments in R&D activities, advancements in cell- and bead-based technologies, growing patient population, and increasing demand for flow cytometry in drug discovery process.  

Region wise, North America accounted for the highest revenue in the flow cytometry market in 2022. The market growth in North America is supplemented by rapid technological advancements, an increase in investments in research & development activities, rise in patient pool, and surge in the number of applications.

However, Asia-Pacific is expected to register the fastest growth during the flow cytometry market forecast. This is mainly attributed to major international companies outsourcing their research processes to contract research organizations (CROs) located in Asia-Pacific. Moreover, impending need for sophisticated healthcare facilities and rise in incidences of chronic diseases such as HIV and cancer are expected to boost the market growth 

Key findings of the study 

• On the basis of components, the reagents and consumables segment dominated the flow cytometry market trends in 2022. 

• On the basis of technology, the cell-based flow cytometry segment was the highest contributor to the market in 2022. 

• On the basis of application, the academic & clinical applications segment was highest contributor to the market in 2022. 

• On the basis of end user, the commercial organizations segment was highest contributor to the market in 2022. 

• On the basis of region, North America generated the largest revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.